Cellosaurus cell line A-375 MEK1 p.Q56P (CVCL

Cellosaurus A-375 MEK1 p.Q56P (CVCL_UD28)

[Text version]

Cell line name

A-375 MEK1 p.Q56P

Synonyms

A-375 MEK1Q56P; MEK1 Mutant-A375 Isogenic Cell Line

Accession

CVCL_UD28

Resource Identification Initiative

To cite this cell line use: A-375 MEK1 p.Q56P (RRID:CVCL_UD28)

Comments

Population: Caucasian.
Characteristics: Exhibits significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib, as well as the MAP2K1 inhibitor trametinib when compared to its parental cell line. Displays increased sensitivity to combination MAP2K1/BRAF inhibitor treatments, making this line an ideal model system for the development of novel combination therapies targeting multiple points in the RAS-RAF-MEK-ERK-MAPK signaling pathway, as well as for the screening of new potential BRAF and MAP2K1 inhibitors (ATCC=CRL-1619IG-3).
Doubling time: ~19 hours (ATCC=CRL-1619IG-3).
Derived from site: In situ; Leg, skin; UBERON=UBERON_0001511.

Sequence variations

Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; HGNC:6840; MAP2K1; Simple_edited; p.Gln56Pro (c.167A>C); ClinVar=VCV000375978; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (ATCC=CRL-1619IG-3).
Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).

Disease

Amelanotic melanoma (NCIt: C3802)

Species of origin

Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy

Parent: CVCL_0132 (A-375)

Sex of cell

Female

Age at sampling

54Y